Inovio Pharmaceuticals Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Inovio Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INO, but not buy additional shares or sell existing shares.
View analyst ratings for Inovio Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Inovio Pharmaceuticals a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Inovio Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Inovio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Inovio Pharmaceuticals.

Inovio Pharmaceuticals will be holding an earnings conference call on Monday, August 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) released its earnings results on Monday, May, 10th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.18) by $0.09. The biopharmaceutical company earned $0.40 million during the quarter, compared to the consensus estimate of $1.06 million. Inovio Pharmaceuticals had a negative net margin of 2,916.64% and a negative trailing twelve-month return on equity of 39.16%. The business's revenue was down 69.2% on a year-over-year basis.
View Inovio Pharmaceuticals' earnings history.

Inovio Pharmaceuticals' stock was trading at $8.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, INO stock has increased by 2.9% and is now trading at $8.61.
View which stocks have been most impacted by COVID-19.

Inovio Pharmaceuticals shares reverse split on the morning of Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

9 analysts have issued 1-year price targets for Inovio Pharmaceuticals' shares. Their forecasts range from $6.00 to $35.00. On average, they expect Inovio Pharmaceuticals' share price to reach $14.89 in the next twelve months. This suggests a possible upside of 72.9% from the stock's current price.
View analysts' price targets for Inovio Pharmaceuticals or view top-rated stocks among Wall Street analysts.

12 employees have rated Inovio Pharmaceuticals CEO J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among Inovio Pharmaceuticals' employees.

Some companies that are related to Inovio Pharmaceuticals include Tandem Diabetes Care (TNDM), ShockWave Medical (SWAV), Integra LifeSciences (IART), Nevro (NVRO), Inspire Medical Systems (INSP), Inari Medical (NARI), ICU Medical (ICUI), AtriCure (ATRC), Merit Medical Systems (MMSI), NuVasive (NUVA), Haemonetics (HAE), Axonics (AXNX), The Beauty Health (SKIN), Glaukos (GKOS) and Silk Road Medical (SILK).
View all of INO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

Inovio Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (0.15%), New York State Common Retirement Fund (0.09%), Advisor Group Holdings Inc. (0.07%), Defender Capital LLC. (0.06%), Green Alpha Advisors LLC (0.03%) and Arizona State Retirement System (0.03%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito.
View institutional ownership trends for Inovio Pharmaceuticals.

INO stock was sold by a variety of institutional investors in the last quarter, including Equitec Specialists LLC, Arizona State Retirement System, Zurcher Kantonalbank Zurich Cantonalbank , and Victory Capital Management Inc.. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner, Jacqueline Elizabeth Shea, Jong Joseph Kim, Laurent Humeau, Lota S Zoth, Peter Kies, and Simon X Benito.
View insider buying and selling activity for Inovio Pharmaceuticals or view top insider-selling stocks.

INO stock was acquired by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Green Alpha Advisors LLC, New York State Common Retirement Fund, Oppenheimer & Co. Inc., Advisor Group Holdings Inc., IFP Advisors Inc, Defender Capital LLC., and Paragon Wealth Strategies LLC. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Jong Joseph Kim, and Laurent Humeau.
View insider buying and selling activity for Inovio Pharmaceuticals or or view top insider-buying stocks.

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INO stock can currently be purchased for approximately $8.61.

Inovio Pharmaceuticals has a market capitalization of $1.80 billion and generates $7.41 million in revenue each year. The biopharmaceutical company earns $-166,410,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

Inovio Pharmaceuticals employs 262 workers across the globe.

The official website for Inovio Pharmaceuticals is www.inovio.com.

Inovio Pharmaceuticals is headquartered at 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462.

Inovio Pharmaceuticals' mailing address is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 858-410-3134 or via email at [email protected]